At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
FX006drug
Likely dose
FX006 5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis
The University of Texas Health Science Center, Houston·interventional·Posted Dec 2, 2019·Updated Jan 2, 2024
In Brief
A Phase 2 clinical trial evaluating FX006 for Trochanteric Bursitis. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of FX006 in bursal injections and to assess the patient's impression to change in their chronic pain, following treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTrochanteric Bursitis
CountriesUnited States
CollaboratorsPacira Pharmaceuticals, Inc
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartAug 2020
Primary CompletionDec 2022
TodayJul 2026
First PostedDec 2, 2019
Enrollment StartAug 12, 2020
Primary CompletionDec 14, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.6 years ago
Interventions
FX006drug
Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.